Stock Scorecard
Stock Summary for Organon & Company (OGN) - $17.82 as of 4/19/2024 8:41:41 PM EST
Total Score
15 out of 29
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for OGN
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for OGN
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for OGN
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for OGN
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for OGN
Financial Details for OGN
Company Overview |
|
|---|---|
| Ticker | OGN |
| Company Name | Organon & Company |
| Country | USA |
| Description | Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, Hormone replacement therapy (HRT), and anesthesia. The company sells to international markets. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 5/2/2024 |
Stock Price History |
|
| Last Day Price | 17.82 |
| Last Day Price Updated | 4/19/2024 8:41:41 PM EST |
| Last Day Volume | 3,612,019 |
| Average Daily Volume | 2,106,723 |
| 52-Week High | 23.21 |
| 52-Week Low | 10.67 |
| Last Price to 52 Week Low | 67.01% |
Valuation Measures |
|
| Trailing PE | 4.46 |
| Industry PE | 100.90 |
| Sector PE | 61.34 |
| 5-Year Average PE | 3.22 |
| Free Cash Flow Ratio | 6.58 |
| Industry Free Cash Flow Ratio | 12.64 |
| Sector Free Cash Flow Ratio | 30.17 |
| Current Ratio Most Recent Quarter | 1.54 |
| Total Cash Per Share | 2.71 |
| Book Value Per Share Most Recent Quarter | -0.27 |
| Price to Book Ratio | 1.84 |
| Industry Price to Book Ratio | 5.66 |
| Sector Price to Book Ratio | 22.08 |
| Price to Sales Ratio Twelve Trailing Months | 0.71 |
| Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.19 |
Share Statistics |
|
| Total Shares Outstanding | 255,638,000 |
| Market Capitalization | 4,555,469,160 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | 2/23/2024 |
| Last Dividend Amount | 0.28 |
| Current Dividend Amount | 0.28 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 1.12 |
| Trailing Annual Dividend Yield | 6.29% |
| Forward Annual Dividend Rate | 1.58 |
| Forward Annual Dividend Yield | 8.89% |
| 5-Year Dividend Payments Count | 11 |
| 3-Year Average Dividend Yield | 4.54% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 41.42% |
| 5-Year Dividend Growth Rate Percentage | 41.42% |
| All-Time Dividend Growth Rate Percentage | 41.42% |
| Dividend Payout Ratio | 28.07% |
Income Statement |
|
| Quarterly Earnings Growth YOY | 406.00% |
| Annual Earnings Growth | 11.56% |
| Reported EPS 12 Trailing Months | 3.99 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | 4.14 |
| Net Income Twelve Trailing Months | 1,023,000,000 |
| Net Income Past Year | 1,023,000,000 |
| Net Income Prior Year | 917,000,000 |
| Quarterly Revenue Growth YOY | 7.60% |
| 5-Year Revenue Growth | -0.33% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 693,000,000 |
| Total Cash Past Year | 693,000,000 |
| Total Cash Prior Year | 706,000,000 |
| Net Cash Position Most Recent Quarter | -8,067,000,000 |
| Net Cash Position Past Year | -8,067,000,000 |
| Long Term Debt Past Year | 8,760,000,000 |
| Long Term Debt Prior Year | 8,913,000,000 |
| Total Debt Most Recent Quarter | 8,760,000,000 |
| Equity to Debt Ratio Past Year | -0.01 |
| Equity to Debt Ratio Most Recent Quarter | -0.01 |
| Total Stockholder Equity Past Year | -70,000,000 |
| Total Stockholder Equity Prior Year | -892,000,000 |
| Total Stockholder Equity Most Recent Quarter | -70,000,000 |
Options |
|
| Put/Call Ratio | 0.38 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.08 |
| 20-Day Bollinger Lower Band | 12.09 |
| 20-Day Bollinger Middle Band | 16.38 |
| 20-Day Bollinger Upper Band | 20.67 |
| Beta | 0.79 |
| RSI | 49.17 |
| 50-Day SMA | 17.23 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 4/18/2024 7:57:38 AM EST |